Company: BLTE
Filing Date: 2025-10-22
Form Type: F-3ASR
Source: 0001104659-25-101403
Chunk: 26

Company: BELITE BIO, INC
Filing Date: 2025-10-22
Form: F-3ASR
Chunk 26
---
           | ​ |  282,270 | ​ | ​ |
| Total capitalization                 | ​ | ​ | ​                   | ​ |  149,885 | ​ | ​ | ​ | ​           | ​ |  282,270 | ​ | ​ |

The above discussion and table are based on 32,599,298 ordinary shares (including ordinary shares represented by ADSs) outstanding as of June 30, 2025 and excludes the following as of that date: • 5,548,977 ordinary shares subject to options outstanding under the Company’s 2020 Amended and Restated Share Incentive Plan and 2022 Performance Incentive Plan; • 186,986 ordinary shares available for grant under the Company’s 2022 Performance Incentive Plan; • 210,000 unvested restricted share units under the Company’s 2022 Performance Incentive Plan; • 1,345,658 ordinary shares (including ordinary shares represented by ADSs) to be issued upon the exercise of warrants outstanding (including the warrants issued in the 2025 August RDO, while excluding the Warrants issued in the 2025 September PIPE); and • any ordinary shares (including ordinary shares represented by ADSs) issuable upon exercise of the Warrants, which are registered on the registration statement of which this prospectus forms a part.

18

TABLE OF CONTENTS

### DESCRIPTION OF SHARE CAPITAL
We are a Cayman Islands exempted company incorporated with limited liability and our affairs are governed by our memorandum and articles of association, the Companies Act (As Revised) of the Cayman Islands, which we refer to as the Companies Act below, and the common law of the Cayman Islands.

As of the date of this prospectus, our authorized share capital is US$50,000 divided into 500,000,000 shares comprised of (i) 400,000,000 ordinary shares of a par value of US$0.0001 each, and (ii) 100,000,000 undesignated shares of a par value of US$0.0001 each of such class or classes (however designated) as the board of directors may determine in accordance with our third amended and restated memorandum and articles of association. As of September 30, 2025, 34,903,104 ordinary shares were issued and 34,890,991 ordinary shares were outstanding. All of our issued and outstanding ordinary shares are fully paid.

Our Third Amended